Joseph Catlett

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

Karl D. Lewis, Wolfram E. Samlowski, John F. Ward et al. · Investigational New Drugs · 2009 · 143 citations

Veterinary Medicine, Molecular Biology, Oncology +14

Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage.

Anita Aggarwal, Vera Malkovska, Joseph Catlett et al. · Thrombosis Journal · 2004 · 66 citations · Full text

Medicine, Hematology, Surgery +17

c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines.

Howard K. Plummer, Joseph Catlett, Julie A. Leftwich et al. · PubMed · 1993 · 63 citations

Medicine, Molecular Biology, Oncology +17

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

Medicine, Oncology, Pharmacotherapy +12

Primary lymphoma of bone: an institutional experience

Joseph Catlett, Stephen A. Williams, Shannon C. O'Connor et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2008 · 44 citations

Medicine, Oncology, Chemotherapy +9